Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Liver Transplantation in the setting
of HIV infection
Eric Vibert, MD, PhD
Hopital Paul Brousse, AP/HP
Villejuif, France
Summary
• Epidemiology of liver disease in HIV+ patient
• Why liver transplantation is feasible HIV+ patient ?
• Result of...
Epidemiology of liver disease in
HIV patient
1996 : Highly Active Anti-Retroviral
Therapy (HAART) in HIV patients
Giordano et al. Arch Int Med 2008
HIV/HCV
HIV
HIV/HCV...
Rate of ELD and HCC in HIV/HVC
Ioannou et al. Hepatology 2013
6% of End-Stage Liver Disease 1.6% of Hepatocellular carcino...
Why LT is feasible in HIV ?
Survival is dependent of MELD Score and not HIV status
1999 to 2005 : 35 HIV/HVC coinfected patients transplanted
2008
Similar mortality on waiting list in HIV
patients listed without HCC in US
2003 – 2007 : 20 transplant centers in US : 167...
Subramanian et al. Gastroenterology 2010
Indication of LT in 132 HIV+ Patients
in Paul Brousse Hospital, France
Indication of Liver Transplantation N (%)
HVC Cirrh...
No impact of Infection on Survival in
109 HIV+ transplanted patients
4/109 (3.6%) developed opportunistic infection with a...
Cause of 43 deaths after LT
1-year patient mortality : 7%
3-year patient mortality : 33%
5-year patient mortality : 39%
Te...
Pre-LT Status RR (IC95%) p
Psoas Area < 1500 4.8 (1.3 – 17.9) 0.018
MELD > 17 3.9 (1.1 – 14.3) 0.033
HBV vs Non HBV 7.2 (1...
Result of LT in End Stage Liver
disease in HIV patient ?
Author
Journal Year n
Survival (%)
1yr 3 yrs
Fung et al.
Liver Transplant 2004
3 100
-
Norris et al.
Liver Transplant 2004...
Miro et al. J Hepatol 2014
HIV impact survival in LT with HCV
Survival near from the ethical limit of 50% of survival at 5...
Higher rate and more severe
recurrence of HVC after LT in HIV
Progression to Fibrosis after LT for
HVC with or without HIV...
Sofosbuvir-based regimens in 16 HIV/HCV
co-infected patients after liver transplantation:
ANRS CO23 CUPILT study
TM Antoni...
HCV virological response
13%
40%
73%
81%
100% 100%
94% 94%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100% *
*virological rela...
Castells et al. J Hepatol 2015
78 HIV/HCV coinfected patients treated before New HVC treatment
New HVC treatment will dras...
Results of LT for HCC in HIV patient
1992 to 2006 : 63 patients in 6 centers
Survival are similar and treatment is usefull
2007
Higher Rate of Infiltrative HCC in HIV
Lewin et al. Radiology 2015
2008 – 2012 : French multicentric prospective study of ...
Lewin et al. Radiology 2015
Correlation with low CD4 rate and
infiltrative HCC tumor
Lewin et al. Radiology 2015
CD4 < 200 cell/µL without portal hype...
Intent-to-treat result analysis : 21 listed then 16 HIV transplanted for HCC
LT for HCC in HIV+ patient
Vibert et al. Hepa...
Significant higher rate of Drop-out
on waiting-list in HIV+ patients
Drop-out : 5/21 (23%) in HIV+ vs 7/65 (10%) in HIV- ,...
Trend for lower survival in HIV+ but not
significant after LT for HCC
Vibert et al. Hepatology 2011
Similar Time to Recurrence in HIV+
Vibert et al. Hepatology 2011
Close follow-up of AFP and imagery
on waiting time period
AFP kinetic > 15 µg/L by month and/or AFP > 1000 µg/L : Control ...
2002-2014 : Spanish Multicentric Study : 74 HIV+ and 222 HIV- transplanted for HCC
Agero et al. Hepatology 2016
Re Transplantation in HIV+ ?
No reLT in HIV+ with HCV RNA+
Aguero et al. Am J Transp 2015
42 reLT (7%) / 600 LT in HIV+14 reLT in HIV+ vs 157 reLT in H...
HVC RNA+ was the only predictor of
mortality in 42 reLT in HIV+
Causes of reLT : Vascular Compl (35%) / PNF (22%) / Reject...
In conclusion
• HAART in HIV from 1996 had doubled the risk
of End-Stage Liver Disease and HCC
• MELD score and Sarcopenia...
Liver Transplantation in the setting of HIV infection
Upcoming SlideShare
Loading in …5
×

Liver Transplantation in the setting of HIV infection

569 views

Published on

Conf about LT in HIV patient presented at IHPBA 2016 in Sao Paulo

Published in: Health & Medicine
  • Be the first to comment

Liver Transplantation in the setting of HIV infection

  1. 1. Liver Transplantation in the setting of HIV infection Eric Vibert, MD, PhD Hopital Paul Brousse, AP/HP Villejuif, France
  2. 2. Summary • Epidemiology of liver disease in HIV+ patient • Why liver transplantation is feasible HIV+ patient ? • Result of LT in HIV for End-Stage Liver Disease – Impact of new treatment of HVC • Result of LT in HIV for Hepatocellular Carcinoma • Retransplantation in HIV patient
  3. 3. Epidemiology of liver disease in HIV patient
  4. 4. 1996 : Highly Active Anti-Retroviral Therapy (HAART) in HIV patients Giordano et al. Arch Int Med 2008 HIV/HCV HIV HIV/HCV HIV Incidence of Cirrhosis before 1996 3.4% 6.1% Incidence of Cirrhosis after 1996 1991 – 2000 : 16 439 HIV in US Veteran Database with or with HVC
  5. 5. Rate of ELD and HCC in HIV/HVC Ioannou et al. Hepatology 2013 6% of End-Stage Liver Disease 1.6% of Hepatocellular carcinoma Stable incidence from 2004 Increasing incidence from 2004 1996 to 2009 : Incidence of cirrhosis and HCC in VIH pts in US Database (n=24040 in 2009)
  6. 6. Why LT is feasible in HIV ?
  7. 7. Survival is dependent of MELD Score and not HIV status 1999 to 2005 : 35 HIV/HVC coinfected patients transplanted 2008
  8. 8. Similar mortality on waiting list in HIV patients listed without HCC in US 2003 – 2007 : 20 transplant centers in US : 167 HIV+ matched with 792 HIV- Time to Death Time to Transplant Subramanian et al. Gastroenterology 2010 CD4+ cells > 100/µL and HIV RNA < 50 copies/ml
  9. 9. Subramanian et al. Gastroenterology 2010
  10. 10. Indication of LT in 132 HIV+ Patients in Paul Brousse Hospital, France Indication of Liver Transplantation N (%) HVC Cirrhosis 82 (62%) Hepatocellular Carcinoma 26 (19%) HVB Cirrhosis 9 (7%) Vascular Liver Disorder (Nod Reg Hyperplasia) 5 (4%) Fulminant Hepatitis 4 (3%) Others 6 (4.5%) Period 1998-2015 : 132 / 1893 LT (7%) on HIV+ patients CD4+ > 200 cell/µL or > 100 cell/µL if portal hypertension HIV RNA < 50 copies/ml and No opportunistic infection from 1 year
  11. 11. No impact of Infection on Survival in 109 HIV+ transplanted patients 4/109 (3.6%) developed opportunistic infection with a median delay of 16 months (11-23) without mortality Teicher et al. Transp Inf Dis 2015 85% 81% 63% 57%
  12. 12. Cause of 43 deaths after LT 1-year patient mortality : 7% 3-year patient mortality : 33% 5-year patient mortality : 39% Teicher et al. Transp Inf Dis 2015
  13. 13. Pre-LT Status RR (IC95%) p Psoas Area < 1500 4.8 (1.3 – 17.9) 0.018 MELD > 17 3.9 (1.1 – 14.3) 0.033 HBV vs Non HBV 7.2 (1.1 – 47.7) 0.03 Major impact of Sarcopenia in HIV+ 2007 – 2011 : 56 HIV+ patients transplanted (39 ELD and 17 HCC) in Paul Brousse Hospital Antonini et al. EASL 2013
  14. 14. Result of LT in End Stage Liver disease in HIV patient ?
  15. 15. Author Journal Year n Survival (%) 1yr 3 yrs Fung et al. Liver Transplant 2004 3 100 - Norris et al. Liver Transplant 2004 4 100 - Duclos-Vallée et al. J Hepatol 2006 5 100 - Schreibman et al. Transplantation 2007 8 75 - Roland et al. Am J Transplant 2007 5 100 - Tateo, et al. AIDS 2009 13 100 Author Journal Year n Survival (%) 3 yrs 5 yrs Ragni et al. J Infect Dis 2003 15 57 - De Vera et al. Am J Transpl 2007 27 56 33 Schreibman et al. Transplantation 2007 15 73 - Vennrecci et al. Transpl Proc 2007 12 58 - Duclos-Vallée et al. Hepatology 2008 35 73 51 Terrault et al. Hepatology 2009 81 59 - Important LT survival difference HIV/HBV and HIV/HCV Cooper et al. AIDS 2011 HIV / HBV HIV / HCV
  16. 16. Miro et al. J Hepatol 2014 HIV impact survival in LT with HCV Survival near from the ethical limit of 50% of survival at 5 years
  17. 17. Higher rate and more severe recurrence of HVC after LT in HIV Progression to Fibrosis after LT for HVC with or without HIV infection Duclos-Vallée et al. Hepatology 2008 Very severe HVC recurrence Fibrosis Cholestatic Hepatitis (20% FCS in HIV+ vs 5% in HIV-) No FCH (n=48) FCH (n=11) p<0.004 Mean survival : 26 ± 4.7 months No Survival Antoni et al. Am J Transp 2011
  18. 18. Sofosbuvir-based regimens in 16 HIV/HCV co-infected patients after liver transplantation: ANRS CO23 CUPILT study TM Antonini, A Coilly, E Rossignol, C Fourgerou-Leurent, S Radenne, A Veislinger, D Botta-Fridlund, F Durand, P Houssel-Debry, N Kamar, V Canva, P Perré, V De Ledinghen, I Bertucci, A Diallo, J Dumortier, V Leroy, D Samuel, GP Pageaux and JC Duclos-Vallée
  19. 19. HCV virological response 13% 40% 73% 81% 100% 100% 94% 94% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% * *virological relapse: G1a , SOF/RBV 24W, FCH W: week; SVR: sustained virological response
  20. 20. Castells et al. J Hepatol 2015 78 HIV/HCV coinfected patients treated before New HVC treatment New HVC treatment will drastically improved result of LT in HVC/HIV Before New Drugs
  21. 21. Results of LT for HCC in HIV patient
  22. 22. 1992 to 2006 : 63 patients in 6 centers Survival are similar and treatment is usefull 2007
  23. 23. Higher Rate of Infiltrative HCC in HIV Lewin et al. Radiology 2015 2008 – 2012 : French multicentric prospective study of 35 HIV/HCV cirrhotic patients with HCC
  24. 24. Lewin et al. Radiology 2015
  25. 25. Correlation with low CD4 rate and infiltrative HCC tumor Lewin et al. Radiology 2015 CD4 < 200 cell/µL without portal hypertension Not candidate for LT
  26. 26. Intent-to-treat result analysis : 21 listed then 16 HIV transplanted for HCC LT for HCC in HIV+ patient Vibert et al. Hepatology 2011 2003-2008 : 147 listed for HCC in Paul Brousse Hosp : 65 (75%) HIV- and 21 (24%) HIV+
  27. 27. Significant higher rate of Drop-out on waiting-list in HIV+ patients Drop-out : 5/21 (23%) in HIV+ vs 7/65 (10%) in HIV- , p = 0.04 Vibert et al. Hepatology 2011
  28. 28. Trend for lower survival in HIV+ but not significant after LT for HCC Vibert et al. Hepatology 2011
  29. 29. Similar Time to Recurrence in HIV+ Vibert et al. Hepatology 2011
  30. 30. Close follow-up of AFP and imagery on waiting time period AFP kinetic > 15 µg/L by month and/or AFP > 1000 µg/L : Control AFP before LT, especially in HIV+ Vibert et al. Am J Trans 2010 Duvoux et al. Gastroenterology 2012
  31. 31. 2002-2014 : Spanish Multicentric Study : 74 HIV+ and 222 HIV- transplanted for HCC Agero et al. Hepatology 2016
  32. 32. Re Transplantation in HIV+ ?
  33. 33. No reLT in HIV+ with HCV RNA+ Aguero et al. Am J Transp 2015 42 reLT (7%) / 600 LT in HIV+14 reLT in HIV+ vs 157 reLT in HIV- in patient wih detectable HVC RNA Gastaca et al. Am J Transp 2012
  34. 34. HVC RNA+ was the only predictor of mortality in 42 reLT in HIV+ Causes of reLT : Vascular Compl (35%) / PNF (22%) / Rejection (19%) / HVC Recurrence (13%) Aguero et al. Am J Transp 2015
  35. 35. In conclusion • HAART in HIV from 1996 had doubled the risk of End-Stage Liver Disease and HCC • MELD score and Sarcopenia was predictive of survival in LT for End-Stage Liver Disease – New HVC drugs used after LT will change the futur • LT for HCC in HIV+ patients must be performed after a closed follow-up of AFP before LT

×